SignatureFD’s Caris Life Sciences CAI Stock Holding History

SignatureFD’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.74K	Hold	220	–	–	﹤0.01%	2851
2026 Q2	$3.92K	Hold	220	–	–	﹤0.01%	2939
2026 Q1	$3.93K	Buy	+220	New	+$4.81K	﹤0.01%	2860

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

SignatureFD's CAI Position: Q3 2026 in Review

SignatureFD held its Caris Life Sciences (CAI) position steady in Q3 2026 at 220 shares worth $6.74K. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

SignatureFD first reported a position in CAI in Q1 2026 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold CAI as of Q3 2026.

SignatureFD held 220 shares of Caris Life Sciences worth $6.74K as of Q3 2026.
SignatureFD left its Caris Life Sciences share count unchanged in Q3 2026.
Caris Life Sciences made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2851 holding.
SignatureFD first reported a position in Caris Life Sciences in Q1 2026 and has held it in 3 quarters since.
166 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.